A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, researchers at Cedars-Sinai Medical Center reported Tuesday.
The researchers also demonstrated in mice that the drug, called Metavert, may prevent patients from developing a resistance to currently used pancreatic cancer chemotherapies, according to lead study author Dr. Mouad Edderkaoui.
“This is an exciting step toward improving survival rates in pancreatic cancer patients,” said Edderkaoui, assistant professor of Medicine and Biomedical Sciences at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. “If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma — PDAC — which is very difficult to treat.”
The researchers, whose study was published recently in the journal Gastroenterology, currently are developing a version of the drug to test in humans, according to the medical center.
Pancreatic cancer is the third-leading cause of cancer-related death in the United States, according to the American Cancer Society. This year, about 55,000 people in the U.S. will be diagnosed with the disease and more than 44,000 will die, making it one of the deadliest cancers. The pancreatic cancer five-year survival rate is 7 percent.
Ninety-five percent of pancreatic cancer patients are diagnosed with PDAC, which develops from cells lining small tubes in the pancreas. PDAC can be difficult to treat because the cancer cells prompt normal cells that reside in the pancreas — called stellate cells — to produce pancreatic scar tissue.
Scar tissue makes it difficult for chemotherapy agents and blood to enter the pancreas, said study senior author Dr. Stephen J. Pandol, a professor of medicine and director of Basic and Translational Pancreas Research at Cedars-Sinai.
The cancer and stellate cell interaction also creates an environment that stimulates local tumor growth and cancer spread to distant sites in the body, according to Pandol. Additionally, the activity levels of certain enzymes rev up, fueling resistance to cancer treatments, he said.
“I’ve seen patients who respond to therapy for a while, and then the disease takes off because the cancer becomes smart — it blocks chemotherapy from working,” Pandol said. “Metavert targets that action.”